Burney Co. lifted its stake in Merck & Co., Inc. (NYSE:MRK) by 11.6% in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 33,188 shares of the company’s stock after purchasing an additional 3,457 shares during the quarter. Burney Co.’s holdings in Merck & Co., Inc. were worth $2,015,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Clearwater Capital Advisors LLC purchased a new position in Merck & Co., Inc. during the 1st quarter valued at $103,000. SRS Capital Advisors Inc. boosted its holdings in Merck & Co., Inc. by 208.4% during the 1st quarter. SRS Capital Advisors Inc. now owns 1,983 shares of the company’s stock valued at $108,000 after acquiring an additional 1,340 shares during the period. Taylor Wealth Management Partners purchased a new position in Merck & Co., Inc. during the 2nd quarter valued at $110,000. Creative Financial Designs Inc. ADV boosted its holdings in Merck & Co., Inc. by 155.2% during the 2nd quarter. Creative Financial Designs Inc. ADV now owns 1,832 shares of the company’s stock valued at $111,000 after acquiring an additional 1,114 shares during the period. Finally, Well Done LLC purchased a new position in Merck & Co., Inc. during the 1st quarter valued at $115,000. Hedge funds and other institutional investors own 72.18% of the company’s stock.

MRK has been the subject of a number of recent analyst reports. Zacks Investment Research cut Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Monday, June 18th. Jefferies Financial Group reaffirmed a “hold” rating and set a $59.00 target price on shares of Merck & Co., Inc. in a research report on Sunday, July 15th. BMO Capital Markets reaffirmed a “buy” rating and set a $70.00 target price on shares of Merck & Co., Inc. in a research report on Sunday, July 22nd. Bank of America lifted their target price on Merck & Co., Inc. from $70.00 to $74.00 and gave the company a “buy” rating in a research report on Monday, July 30th. Finally, SunTrust Banks reaffirmed a “buy” rating and set a $77.00 target price on shares of Merck & Co., Inc. in a research report on Thursday, August 16th. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $69.61.

Shares of NYSE MRK opened at $69.81 on Friday. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.33 and a quick ratio of 1.04. The firm has a market cap of $191.27 billion, a price-to-earnings ratio of 17.54, a PEG ratio of 2.22 and a beta of 0.81. Merck & Co., Inc. has a twelve month low of $52.83 and a twelve month high of $72.89.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Friday, July 27th. The company reported $1.06 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.03 by $0.03. The business had revenue of $10.47 billion during the quarter, compared to analyst estimates of $10.28 billion. Merck & Co., Inc. had a return on equity of 32.68% and a net margin of 3.67%. Merck & Co., Inc.’s revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.01 EPS. Research analysts expect that Merck & Co., Inc. will post 4.27 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, October 5th. Stockholders of record on Monday, September 17th were given a $0.48 dividend. This represents a $1.92 annualized dividend and a dividend yield of 2.75%. The ex-dividend date of this dividend was Friday, September 14th. Merck & Co., Inc.’s payout ratio is 48.24%.

In other news, Chairman Kenneth C. Frazier sold 228,091 shares of the business’s stock in a transaction on Tuesday, July 31st. The stock was sold at an average price of $65.00, for a total value of $14,825,915.00. Following the completion of the transaction, the chairman now directly owns 938,788 shares of the company’s stock, valued at approximately $61,021,220. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Chairman Kenneth C. Frazier sold 279,850 shares of the business’s stock in a transaction on Tuesday, October 2nd. The stock was sold at an average price of $72.07, for a total value of $20,168,789.50. Following the completion of the transaction, the chairman now directly owns 971,800 shares of the company’s stock, valued at $70,037,626. The disclosure for this sale can be found here. Over the last three months, insiders sold 929,360 shares of company stock valued at $64,370,599. Corporate insiders own 0.32% of the company’s stock.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Featured Article: Book Value Of Equity Per Share – BVPS Explained

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.